ORLANDO, Fla.—The efforts of pharmacy benefit managers (PBMs) and drug manufacturers to constrain the federal 340B Drug Pricing Program are costing some larger urban hospitals more than $21 million annually, experts said at the NASP 2022 Annual Meeting & Expo.
Insurers and PBMs that administer their own pharmacy benefit have increasingly implemented reduced reimbursement rates on 340B drug claims, said Peggy Tighe, JD, of Powers Pyles Sutter & Verville.
“This